Stock Financial Ratios, Dividends, Split History

P / Pandora Media, Inc. financial ratios include Market Cap, Enterprise Value, Book Value, Quick Ratio, Current Ratio, NCAV, EBITDA, Profit Margin, Operating Margin, Return on Invested Capital (ROIC), Return on Assets (ROA), Return on Equity (ROE), Piotroski F-Score, Altman Z-Score, Beneish M Score and Kaplan-Zingales KZ-Index.

Valuation Metrics
Market Cap ($M)1,898.85
Book Value ($M)670.40
Book Value / Share2.93
Price / Book2.81
NCAV ($M)113.26
NCAV / Share0.50
Price / NCAV16.62
Share Statistics
Common Stock Shares Outstanding 224,970,412
Common Shares Outstanding 227,695,644
Scoring Models
Piotroski F-Score1.00
Altman Z ScoreN/A
Beneish M ScoreN/A
Management Effectiveness (mra)
Return on Invested Capital (ROIC)-0.17
Return on Assets (ROA)-0.23
Return on Equity (ROE)-0.29
Balance Sheet (mrq) ($M)
Quick Ratio2.53
Current Ratio2.53
Income Statement (mra) ($M)
Advertising Revenue933,305,000.00
Service And Processing Revenue10,167,000.00
Sales Revenue Net1,164,043,000.00
Sales Revenue Services Net0.00
Subscription Revenue220,571,000.00
Operating Income-169.99
Net Income-169.66
Earnings Per Share Basic And Diluted-0.79
Earnings Per Share Diluted-0.79
Earnings Per Share Basic-0.79
Cash Flow Statement (mra) ($M)
Cash From Operations-42.08
Cash from Investing-102.27
Cash from Financing-42.08
Identifiers and Descriptors
Central Index Key (CIK)1230276
Related CUSIPS
698354957 698354907

Split History

Stock splits are used by Pandora Media, Inc. to keep share prices within reasonable numbers to encourage investment. If the share price of a security gets too high, a company can perform a stock split by issuing all shareholders an extra share, thereby halving the price of an individual share. If the share price gets too low, companies can do reverse splits. This is common when share prices drop below $1.00 and company's become in danger of being delisted. However, because of the cost, stock splits are not a normal business occurrence.

Coming soon
P : Pandora Media Stock Analysis and Research Report

2017-11-09 - Asif

Pandora is the world’s most powerful music discovery platform, offering a personalized experience for each of its listeners wherever and whenever they want to listen to music—whether through earbuds, car speakers or home audio/video equipment. The company's vision is to be the definitive source of music discovery and enjoyment for billions of users. Pandora is available as an ad-supported service, a radio subscription service called Pandora Plus and an on-demand subscription service called Pandora Premium. The majority of its listener hours occur on mobile devices, with the majority of its revenue generated from advertising on its ad-supported service on these devices. The company offer both local and national advertisers the opportunity to deliver targeted messages to its listeners using a combination of audio, display and video advertisements. The company also generate revenue from subscriptions to Pandora Plus and Pandora Premium. Founded by musicians, Pandora also empowers artists ...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

These 4 Penny Stocks May Very Well Be Worth the Risk

2018-07-19 investorplace
After all, there is a reason penny stocks have plunged to trade below $10. And that reason isn’t a good one. Stocks don’t IPO below $10. So, if you’re looking at penny stocks below $10, always remember that the stock got there because investors sold it off to that point. (17-0)

Best Buy Should Be Dead, But It’s Thriving in the Age of Amazon - Bloomberg

2018-07-19 bloomberg
Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world. (9-0)

4 Stocks That Could Get Crushed by Amazon in the Long Run | InvestorPlace

2018-07-11 investorplace
On its march towards world domination, e-retail and cloud giant Amazon (NASDAQ:AMZN) is disrupting a whole bunch of industries and creating tough times for companies of all shapes and sizes. (62-0)

Sonos IPO: Patented Technology And 10% Revenue Growth In 2017

2018-07-10 seekingalpha
Experts estimate that global paid subscribers to streaming music services will grow from 176 million in 2017 to 293 million by 2021. (67-0)

Is Hawaiian Holdings A Better Airline Buy Than American Airlines?

2018-07-10 seekingalpha
This study of stock price compounding and information compounding says maybe not. American Airlines (AAL) may be trivially better. (28-0)

CUSIP: 698354107